Addex Therapeutics Files 6-K Report
Ticker: ADXN · Form: 6-K · Filed: Apr 21, 2026 · CIK: 0001574232
| Field | Detail |
|---|---|
| Company | Addex Therapeutics Ltd. (ADXN) |
| Form Type | 6-K |
| Filed Date | Apr 21, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: foreign-issuer, regulatory-filing, press-release
TL;DR
Addex Therapeutics filed a 6-K on 4/21/26 with a press release. Check for updates.
AI Summary
Addex Therapeutics Ltd. filed a Form 6-K on April 21, 2026, reporting information as a foreign issuer. The filing includes a press release as Exhibit 99.1, detailing recent company activities and financial updates. The company's mailing and business address is CHEMIN DES MINES 9, GENEVA V8, CH-1202.
Why It Matters
This filing provides an update from Addex Therapeutics, a foreign issuer, which may contain material information relevant to investors and stakeholders.
Risk Assessment
Risk Level: low — A 6-K filing is a routine report for foreign issuers and typically contains updates rather than significant new risks.
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Filer
- 0001574232 (company) — CIK Number
- 2026-04-21 (date) — Filing Date
- CHEMIN DES MINES 9 GENEVA V8 CH-1202 (address) — Mailing and Business Address
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign issuer required by SEC rules 13a-16 and 15d-16, used to submit information that the issuer makes or is required to make public in its home country.
What is the accession number for this filing?
The SEC Accession No. for this filing is 0001171843-26-002589.
What document is included as Exhibit 99.1?
Exhibit 99.1 is a press release (f6k_042126.htm).
What is Addex Therapeutics Ltd.'s CIK number?
Addex Therapeutics Ltd.'s CIK number is 0001574232.
What is the company's state of incorporation and fiscal year end?
The company's state of incorporation is V8 and its fiscal year ends on December 31 (1231).
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 21, 2026 regarding Addex Therapeutics Ltd. (ADXN).